The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
== Chemical synthesis == The industrial synthesis combines acrolein, methanethiol, and cyanide, which affords the hydantoin. Racemic methionine can also be synthesized from diethyl sodium phthalimidomalonate by alkylation with chloroethylmethylsulfide (ClCH2CH2SCH3) followed by hydrolysis and decarboxylation. Also see Methanol.
Under the United States Federal Analogue Act, compounds which are analogues of and "substantially similar" to Schedule I and Schedule II controlled substances may themselves be treated as Schedule I controlled substances. Consequent to this law, such substances may be considered illegal to sell, purchase, or possess. However, the law applies only if the compounds are intended for human consumption. The Federal Analogue Act has been considered "void for vagueness" as the meaning of "substantially similar" is not precisely defined. In addition, the law only applies to compounds explicitly intended for human consumption. As a result, if compounds are not marketed this way, they can still be legally sold. This has resulted in such compounds being marketed as "research chemicals", "bath salts", "plant food", and "not for human consumption", even though they actually are intended for human use. Such flaws have limited the law and led to calls for reform.
ECD devices can be of two forms. It can trap analyte ions during the ECD stage or can undergo flow through mode where dissociation takes place as analyte ions flows continuously through the ECD region. Flow through mode has advantage over other mode because nearly all the analyte ion beam is used. However, that decreases the efficiency of ECD for flow through mode. ECD produces significantly different types of fragment ions (although primarily c- and z-type, b-ions have been identified in ECD) than other MS/MS fragmentation methods such as electron-detachment dissociation (EDD) (primarily a and x types), collision-induced dissociation (CID) (primarily b and y type) and infrared multiphoton dissociation. CID and IRMPD introduce internal vibrational energy in some way or another, causing loss of post-translational modifications during fragmentation. In ECD, unique fragments (and complementary to CID) are observed, and the ability to fragment whole macromolecules effectively has been promising. Although ECD is primarily used in Fourier transform ion cyclotron resonance mass spectrometry, investigators have indicated that it has been successfully used in an ion-trap mass spectrometer. ECD can also do rapid integration of multiple scans in FTICR-MS if put in a combination with external accumulation. ECD is a recently introduced MS/MS fragmentation technique and is still being investigated.
Dimethocaine, also known as DMC or larocaine, is a compound with local anesthetic and stimulatory effects. The stimulatory effect resembles that of cocaine, although less potent. Similarly to cocaine, dimethocaine is addictive due to its stimulation of the reward pathway in the brain. However, dimethocaine is a legal cocaine replacement in some countries and is listed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) under the "synthetic cocaine derivatives" category. The structure of dimethocaine, being a 4-aminobenzoic acid ester, resembles that of procaine. It is found as a white powder at room temperature. When a product sold online in the UK in June 2010, advertised as dimethocaine was tested, it was found to be a mixture of caffeine and lidocaine, and the lack of any dopaminergic stimulant ingredient in such mixes may explain the limited recreational effects reported by many users. Other samples tested have however been shown to contain genuine dimethocaine, and one branded "bath salt" product containing primarily dimethocaine as the active ingredient, was noted to have been particularly subject to abuse by intravenous drug users in Ireland.
One day later, scientists quantify global and local mass extinction risks of marine life from climate change and conservation potentials. Researchers report routes for recycling 200 industrial waste chemicals into important drugs and agrochemicals using a software for computer-aided chemical synthesis design, helping enable "circular chemistry" as a potential area of a circular economy. 28 April A comprehensive review reaffirms likely beneficial health effects with links to health/life extension of cycles of caloric restriction and intermittent fasting as well as reducing meat consumption in humans. It identifies issues with contemporary nutrition research approaches, proposing a multi-pillar approach, and summarizes findings towards constructing – multi-system-considering and at least age-personalized dynamic – refined longevity diets and proposes inclusion of such in standard preventive healthcare. A company reports results of a phase 3 clinical trial, indicating that tirzepatide could be used for substantial weight loss – possibly larger than the, as of 2022 also expensive, semaglutide approved by the FDA in 2021 – in obese people. Researchers publish projections for interspecies viral sharing, that can lead to novel viral spillovers, due to ongoing climate change-caused range-shifts of mammals (mostly bats) for use in efforts of pandemic prevention.
Sources: en.wikipedia.org
=== Screening === It is unclear if screening pregnant women for iron-deficiency anemia during pregnancy improves outcomes in the United States. The same holds for screening children who are 6 to 24 months old. Even so, screening is a Level B recommendation suggested by the US Preventive Services Task Force in pregnant women without symptoms and in infants considered high risk. Screening is done with either a hemoglobin or hematocrit lab test.
NASA at first intended to launch one more mission, extending the spacecraft's endurance to three days, but since this would not beat the Soviet record, it was decided instead to concentrate on developing Project Gemini.
Pakistan provided support to Saudi Arabia during the Gulf War. Pakistan chose to remain neutral during Operation Decisive Storm, refraining from sending military support to Saudi Arabia in its offensive against Yemen. Instead, Pakistan aimed to play a proactive diplomatic role in resolving the crisis, which led to tensions between the two countries. In 2016, Pakistan mediated between Saudi Arabia and Iran following the execution of Shia cleric Nimr al-Nimr, with visits to both countries by then Prime Minister Nawaz Sharif and the Chief of Army Staff, Raheel Sharif. Pakistan provided refuge to millions of displaced Afghans after the Soviet invasion and supported the Afghan mujahideen in their efforts to expel Soviet forces from Afghanistan. After the Soviets withdrew, infighting erupted among Mujahideen factions over control of Afghanistan. Pakistan facilitated peace talks to help end the conflict. After four years of unresolved conflict between rival Mujahideen groups, Pakistan helped establish the Taliban as a stabilising force. Pakistan's support for the Sunni Taliban in Afghanistan challenged Shia-led Iran, which opposed a Taliban-controlled Afghanistan. Pakistan vigorously advocated for self-determination among Muslims globally. Its efforts in supporting independence movements in countries like Indonesia, Algeria, Tunisia, Morocco, and Eritrea fostered strong ties. Due to its support for Azerbaijan in the Nagorno-Karabakh conflict, Pakistan has not established diplomatic relations with Armenia.
The drug udenafil is marketed under the trade name Zydena. It is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Like other PDE5 inhibitors, it is used to treat erectile dysfunction. Udenafil was developed by Dong-A Pharmaceutical. It has fairly rapid onset of action (peak plasma concentration after 1 to 1.5 hours), and has long duration of action (plasma half-life of 11 to 13 hours). Udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines. It has not yet been approved for use in the United States by the U.S. Food and Drug Administration.
=== Dysplasia === Heart valve dysplasia is an error in the development of any of the heart valves, and a common cause of congenital heart defects in humans as well as animals; tetralogy of Fallot is a congenital heart defect with four abnormalities, one of which is stenosis of the pulmonary valve. Ebstein's anomaly is an abnormality of the tricuspid valve, and its presence can lead to tricuspid valve regurgitation. A bicuspid aortic valve is an aortic valve with only 2 cusps as opposed to the normal 3. It is present in about 0.5% to 2% of the general population and causes increased calcification due to higher turbulent flow through the valve.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.